Tag: growth hormone secretagogue

Research Context

Across the supplied synthesis packet, most ipamorelin literature is review-level or preclinical. The packet did not identify large randomized human trials of ipamorelin for the discussed indications. Any human-relevant statements should remain tied to the specific clinical populations and endpoints discussed in reviews, not generalized across conditions or patient groups.

Direct Answer

• The published record summarized here is dominated by review articles in orthopaedics and sports medicine and by animal studies; human trial support is limited or absent at scale [pubmed:41490200][pubmed:41476424].
• Reviews discuss ipamorelin as a growth hormone secretagogue/ghrelin-mimetic within broader therapeutic peptide frameworks and caution against extrapolating beyond studied contexts [pubmed:41490200][pubmed:41476424][pubmed:32257855].
• Preclinical findings include effects on weight loss in a ferret chemotherapy model, insulin secretion mechanisms in rats, rodent bone growth and bone mineral content, postoperative ileus in rodents, and attenuation of nociception with ghrelin mimetics. These are mechanistic or translational signals, not clinical proof [pubmed:39043357][pubmed:15665799][pubmed:10373343][pubmed:10828840][pubmed:19289567][pubmed:32801950].
• The packet did not identify large randomized human trials; generalized anti-aging or cross-indication efficacy claims are unsupported.

Human Evidence (if any) and Limitations

• Reviews and clinical primers note ipamorelin within the broader class of therapeutic peptides but do not establish generalized clinical efficacy. Where human-relevant discussion exists, conclusions should remain anchored to the specific population, endpoint, and clinical context described in those reviews [pubmed:41490200][pubmed:41476424][pubmed:32257855].
• Explicitly, the packet did not identify large randomized human trials of ipamorelin for the indications discussed here. Therefore, dosing, safety, and broad clinical effectiveness remain incompletely characterized at the human level.

Review and Commentary Literature

• Orthopaedic and sports medicine overviews place ipamorelin among injectable therapeutic peptides, highlighting opportunities and challenges in musculoskeletal care but without constituting primary clinical outcome evidence [pubmed:41490200][pubmed:41476424].
• A review addressing growth hormone secretagogues in hypogonadal males discusses potential roles in body composition management, but this is review-level context rather than primary human trial data for ipamorelin specifically [pubmed:32257855].

Preclinical and Mechanistic Findings (Non-Human)

• Cancer cachexia and emesis: In ferrets with cisplatin-induced weight loss, the GHSR1a agonists anamorelin and ipamorelin both attenuated weight loss; anti-emetic effects were observed for anamorelin via a central mechanism [pubmed:39043357].
• Insulin secretion: In normal and diabetic rats, ipamorelin evoked insulin release via pancreatic mechanisms [pubmed:15665799].
• Bone biology: Rodent studies reported induction of longitudinal bone growth and increased bone mineral content with ipamorelin [pubmed:10373343][pubmed:10828840].
• Gastrointestinal motility: Ipamorelin demonstrated efficacy in a rodent model of postoperative ileus [pubmed:19289567].
• Nociception: Ghrelin mimetics (a class that includes ipamorelin) attenuated visceral and somatic nociception in preclinical models [pubmed:32801950].
• Product quality: Analysis of black-market growth-promoting peptides underscored authenticity and quality concerns in unregulated supply chains [pubmed:29864719].

What Is Not Established

• Direct human efficacy and safety: The packet did not identify large randomized human trials of ipamorelin for the discussed indications. Human dosing, safety profiles, and generalized effectiveness remain inadequately defined.
• Anti-aging and broad indications: Generalized anti-aging or cross-indication claims are not supported by the current literature. Mechanistic plausibility (e.g., ghrelin receptor agonism) does not establish clinical utility.
• Generalization across populations: Any conclusions should remain tied to the specific clinical contexts discussed in reviews; cross-population or cross-condition extrapolation is unsupported [pubmed:41490200][pubmed:41476424][pubmed:32257855].

References

• [pubmed:41490200] Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. https://pubmed.ncbi.nlm.nih.gov/41490200/
• [pubmed:41476424] Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. https://pubmed.ncbi.nlm.nih.gov/41476424/
• [pubmed:39043357] The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism. https://pubmed.ncbi.nlm.nih.gov/39043357/
• [pubmed:15665799] Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats. https://pubmed.ncbi.nlm.nih.gov/15665799/
• [pubmed:32257855] Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. https://pubmed.ncbi.nlm.nih.gov/32257855/
• [pubmed:32801950] Attenuation of Visceral and Somatic Nociception by Ghrelin Mimetics. https://pubmed.ncbi.nlm.nih.gov/32801950/
• [pubmed:10373343] Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. https://pubmed.ncbi.nlm.nih.gov/10373343/
• [pubmed:29864719] Analysis of new growth promoting black market products. https://pubmed.ncbi.nlm.nih.gov/29864719/
• [pubmed:10828840] The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. https://pubmed.ncbi.nlm.nih.gov/10828840/
• [pubmed:19289567] Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. https://pubmed.ncbi.nlm.nih.gov/19289567/

Research-use-only catalog access

KRL product pages are gated and require age and research-use-only acknowledgement before prices, cart, or checkout are available.